Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors
Status:
Completed
Trial end date:
2017-10-10
Target enrollment:
Participant gender:
Summary
Phase I:
The purpose of this research study is to determine the safety of the combination treatment of
ZD6474 (Vandetanib) with the standard therapy for glioblastomas and gliosarcomas,
temozolomide (Temodar) and radiation therapy. This agent is investigational for the treatment
of glioblastomas. We will determine the highest dose of ZD6474 (Vandetanib) that can be given
safely when combined with temozolomide (Temodar) and radiation therapy.
Phase II:
The purpose of this research study is to determine the efficacy of the combination treatment
of ZD6474 (Vandetanib) with the standard therapy for glioblastomas and gliosarcomas,
temozolomide (Temodar) and radiation therapy. This agent is investigational for the treatment
of glioblastomas.
All subjects participating in this research study must NOT be taking a certain type of
anti-seizure medication called enzyme inducing anticonvulsant drugs. These drugs include (but
are not limited to) the following medications: Dilantin, Tegretol, Phenobarbital and
trileptal.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Patrick Y. Wen, MD
Collaborators:
Beth Israel Deaconess Medical Center Dana-Farber Cancer Institute Henry Ford Hospital Massachusetts General Hospital Memorial Sloan Kettering Cancer Center University of Virginia